BCMA is typically prevalent in advanced-stage B-cells and plasma cells and has already been successfully targeted in multiple myeloma, leading to the FDA approval of two BCMA-CAR T-cell therapies: idecabtagene vicleucel (ide-cel)[107] and ciltacabtagene autoleucel (cilta-cel)[108]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.